Sobre 1 señal de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Explore the complete record of transactions filed by Matsuda Masaru, See Remarks. Officer active across 2 companies, notably Arcutis Biotherapeutics, Inc.. Aggregated, 32 reports have been recorded. Split: 1 buy · 19 sells. Total volume traded: €1.6m. History available since 4 September 2021. The latest transaction was filed on 3 August 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Matsuda Masaru
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Matsuda Masaru is a declarant with 31 filings in total. In the recent filings sampled, there were EUR 6,246 of buys and EUR 1,545,203 of sells between 2021-09-07 and 2026-05-06, with Cession as the modal transaction nature. He is associated with Arcutis Biotherapeutics, Inc., where the role is See Remarks, and with Halozyme Therapeutics, INC., where his role is SVP, General Counsel.